Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)

Phase 3bexicaserinPositive

AI Analysis

Summary

Lundbeck announced completion of patient enrollment in DEEp OCEAN, a global Phase 3 trial evaluating investigational bexicaserin for seizures associated with developmental and epileptic encephalopathies. This is described as the broadest pivotal trial to date for this indication.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Last patient randomized in DEEp OCEAN trial

Importance:6/10

Sentiment:

0.60

epilepsydevelopmental and epileptic encephalopathiesPhase 3clinical trialbexicaserin

Related Companies

$HLUYY

Read the original article

Published by PR Newswire Biotech on July 20, 2026 7:42 AM

Read Original